Jacobs Levy Equity Management, Inc Glycomimetics Inc Transaction History

Jacobs Levy Equity Management, Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$1.44 - $2.14 $525,618 - $781,127	-365,013 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$1.8 - $2.39 $64,888 - $86,157	36,049 Added 10.96%	365,013 $799,000
Q2 2021 Aug 16, 2021	SELL	$2.16 - $3.18 $232,366 - $342,094	-107,577 Reduced 24.64%	328,964 $763,000
Q1 2021 May 17, 2021	BUY	$2.89 - $4.22 $341,522 - $498,694	118,174 Added 37.12%	436,541 $1.31 Million
Q4 2020 Feb 16, 2021	BUY	$2.69 - $4.24 $236,865 - $373,348	88,054 Added 38.23%	318,367 $1.2 Million
Q3 2020 Nov 16, 2020	SELL	$3.07 - $5.0 $180,488 - $293,955	-58,791 Reduced 20.34%	230,313 $707,000
Q2 2020 Aug 17, 2020	BUY	$2.06 - $3.76 $419,317 - $765,355	203,552 Added 237.93%	289,104 $1.09 Million
Q1 2020 May 15, 2020	BUY	$1.83 - $5.41 $55,247 - $163,327	30,190 Added 54.53%	85,552 $195,000
Q4 2019 Feb 14, 2020	BUY	$4.03 - $6.5 $223,108 - $359,853	55,362 New	55,362 $293,000

17.7M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $13.6M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.